Table 3.
Comparison of laboratory parameters differing significantly in patients with and without persistent postacute COVID‐19 syndrome at Week 12 of follow‐up
| Persistent postacute COVID‐19 syndrome at Week 12 | |||
|---|---|---|---|
| No | Yes | ||
| (n = 101) | (n = 50) | ||
| Mean ± SD | Mean ± SD | p | |
| WBC (/µl) | 7104.3 ± 1884.5 | 8420.2 ± 2210.4 | <0.001 |
| Neutrophils (/µl) | 3118.1 ± 1612.8 | 5052.4 ± 2004.1 | <0.001 |
| MPV (fl) | 10.2 ± 0.6 | 9.5 ± 0.6 | 0.01 |
| LDH (U/L) | 216 ± 60.1 | 245.7 ± 48.6 | 0.002 |
| D‐dimer (ng/ml) | 303.2 ± 136.5 | 381.2 ± 150.4 | <0.001 |
| Pro‐BNP (pg/ml) | 50.1 ± 66.6 | 75.9 ± 43.2 | <0.001 |
| FVC% | 115.5 ± 15.1 | 98.2 ± 18.9 | <0.001 |
| FEV1% | 110.1 ± 17.4 | 99.2 ± 17.2 | <0.001 |
| DLCO/VA% | 125.3 ± 16.4 | 96.4 ± 26.7 | <0.001 |
| SO2 (%) | 95 ± 1.5 | 91.4 ± 1.8 | <0.001 |
| Heart rate (beats/min) | 88.8 ± 14.6 | 92.1 ± 9.4 | 0.01 |
Abbreviations: %, percent predicted; DLCO/VA, diffusing capacity for carbon monoxide divided by alveolar volume; FEV1: forced expiratory volume in 1 s; FVC, forced vital capacity; LDH, lactose dehydrogenase; MPV, mean platelet volume; SO2, oxygen saturation; WBC, white blood cells.